Surescripts Standardizes on Splunk Software to Target Healthcare Fraud
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/25/2026
- Nasdaq lags on angst over AI spending ahead of earnings reports
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil falls on report China pushing for end US-Iran war
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- AMD (AMD) PT Raised to $1,250 at Baird
- Pakistan, Iran explore path towards new talks with US in a China-initiated push, sources say
- FDA approves Tylenol with Naproxen as first OTC combo pain reliever
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Outlook Therapeutics (OTLK) halted, news pending
Cantor Fitzgerald Remains Bullish Ahead of Splunk's (SPLK) 1Q Report
May 21, 2015 8:47 AM EDTCantor Fitzgerald maintains a Buy rating and $90 price target on Splunk (NASDAQ: SPLK) leading up to its 1Q16 results. Analyst Brian White believes that Splunk will at least meet his 1Q revenue estimate of $120.9m, and EPS estimate of ($0.04). Splunk is scheduled to report 1Q earnings on May... More
